Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study
Background: The use of immune-modifying biological agents has markedly changed the clinical course and the management of Inflammatory bowel diseases (IBDs). Active post-marketing surveillance programs are fundamental to early recognize expected and unexpected adverse events (AEs), representing a pow...
Main Authors: | Martina Tallarico, Caterina Palleria, Livia Ruffolo, Rocco Spagnuolo, Maria Diana Naturale, Adele Emanuela De Francesco, Caterina De Sarro, Rossella Romeo, Rita Citraro, Patrizia Doldo, Ludovico Abenavoli, Luca Gallelli, Francesco Luzza, Antonio Leo, Giovambattista De Sarro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/11/2449 |
Similar Items
-
Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region
by: Agnese Gagliardi, et al.
Published: (2022-10-01) -
Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).
by: Caterina Palleria, et al.
Published: (2018-01-01) -
Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis
by: Francesca Scicchitano, et al.
Published: (2012-01-01) -
Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population
by: Rosa Papadopoli, et al.
Published: (2021-12-01) -
Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
by: Luigi Francesco Iannone, et al.
Published: (2020-01-01)